Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMODREP: Famotidine to Reduce Endothelial P-selectin in Pediatric Sickle Cell Disease
2022-502144-12-00Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of famotidine in sickle cell disease (SCD) and Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in plasma soluble P-selectin concentration. Started Jan 2022; status: completed.
02
Drugs
famotidine
03
Conditions
sickle cell disease (SCD)Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia)
Beyond the preview
Go deeper on 2022-502144-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502144-12-00.